CAR-T Cell Therapy: From the Bench to the Bedside
Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA
Academic Editor: Samuel C. Mok
Received: 27 October 2017 / Revised: 30 October 2017 / Accepted: 30 October 2017 / Published: 31 October 2017
Note: In lieu of an abstract, this is an excerpt from the first page.
CAR (Chimeric Antigen receptor)-T cell therapy is a novel type of therapy that uses engineered T cells with an antibody single-chain variable fragment (ScFv) extracellular domain that binds tumor-associated antigens[...]
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Scifeed alert for new publications
Never miss any articles
matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
Define your Scifeed now
Share & Cite This Article
MDPI and ACS Style
Golubovskaya, V. CAR-T Cell Therapy: From the Bench to the Bedside. Cancers 2017, 9, 150.
Golubovskaya V. CAR-T Cell Therapy: From the Bench to the Bedside. Cancers. 2017; 9(11):150.
Golubovskaya, Vita. 2017. "CAR-T Cell Therapy: From the Bench to the Bedside." Cancers 9, no. 11: 150.
Show more citation formats
Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.